Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Increased pulse rate01:17

Increased pulse rate

Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Premature Ventricular Contractions as a Target for Arrhythmogenic Right Ventricular Cardiomyopathy Trials PVC in ARVC trials.

Heart rhythm·2026
Same author

Pregnancy in the broad phenotype and genotype spectrum of disease-causing desmosomal variant-positive women.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026
Same author

External validation of the DSP-risk score for prediction of clinically significant ventricular arrhythmias in primary prevention patients with desmoplakin cardiomyopathy-associated genetic variants.

Heart rhythm·2026
Same author

RBM20 Truncating Variants and Human Cardiomyopathy.

JAMA cardiology·2026
Same author

Imaging Naxos disease and related cardiocutaneous syndromes: the NAXCARE multimodality approach.

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese·2026
Same author

Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies.

Journal of the American Heart Association·2026

Video Experimental Relacionado

Updated: Jul 9, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

La cardiomiopatía hipertrófica es una cardiomiopatía hipertrófica.

Perry Elliott1, William J McKenna

  • 1University College London, London, UK.

Lancet (London, England)
|June 9, 2004
PubMed
Resumen
Este resumen es generado por máquina.

La cardiomiopatía hipertrófica, una enfermedad cardíaca genética que causa hipertrofia ventricular izquierda inexplicable, tiene resultados variables. Las estrategias de manejo dependen de factores genéticos y condiciones específicas del paciente para una atención óptima.

Más Videos Relacionados

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

Videos de Experimentos Relacionados

Last Updated: Jul 9, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

Área de la Ciencia:

  • Cardiología Cardiología.
  • Genética La genética.
  • Medicina interna es la medicina interna de las enfermedades.

Sus antecedentes:

  • La cardiomiopatía hipertrófica (HCM) es una afección cardíaca hereditaria común caracterizada por una hipertrofia ventricular izquierda inexplicable.
  • La HCM presenta un amplio espectro de manifestaciones clínicas, que van desde casos asintomáticos hasta intolerancia severa al ejercicio y arritmias.
  • La progresión de la enfermedad y las complicaciones, incluida la muerte súbita cardíaca, la insuficiencia cardíaca y el accidente cerebrovascular, conllevan un riesgo anual del 1-2%, influenciado por factores genéticos, patológicos y fisiológicos.

Objetivo del estudio:

  • Revisar el manejo de pacientes diagnosticados con hipertrofia miocárdica inexplicable.
  • Hacer hincapié en el papel de los sustratos genéticos y fisiopatológicos en la orientación de la toma de decisiones clínicas para la cardiomiopatía hipertrófica.

Principales métodos:

  • Revisión de la literatura existente sobre la cardiomiopatía hipertrófica.
  • Análisis de los factores que influyen en el curso clínico y los resultados.
  • Evaluación de las intervenciones terapéuticas basadas en subconjuntos de pacientes.

Principales resultados:

  • El curso clínico y el pronóstico de la HCM son muy variables entre los individuos.
  • La estratificación del riesgo de complicaciones como la muerte súbita, la insuficiencia cardíaca y el accidente cerebrovascular es crucial, pero depende de los factores individuales del paciente.
  • Las intervenciones terapéuticas específicas, como la ablación septal, la miectomía y los desfibriladores cardioverter implantables, están indicadas para grupos selectos de pacientes.

Conclusiones:

  • El asesoramiento genético y la estratificación completa del riesgo clínico son esenciales para todos los pacientes con HCM.
  • Las estrategias de manejo personalizadas, informadas por las anomalías genéticas subyacentes y las características fisiopatológicas, son clave para optimizar los resultados de los pacientes con cardiomiopatía hipertrófica.